Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 2040-2045

  Dorff, Tanya B ^{a,b,c,d,e,f,g,h,i}   Flaig, Thomas W ^{a,b,c,d,e,f,g,h,i}   Tangen, Catherine M ^{a,b,c,d,e,f,g,h,i}   Hussain, Maha H A ^{a,b,c,d,e,f,g,h,i}   Swanson, Gregory P ^{a,b,c,d,e,f,g,h,i}   Wood Jr , David P ^{a,b,c,d,e,f,g,h,i}   Sakr, Wael A ^{a,b,c,d,e,f,g,h,i}   Dawson, Nancy A ^{a,b,c,d,e,f,g,h,i}   Haas, Naomi B ^{a,b,c,d,e,f,g,h,i}   Crawford, E David ^{a,b,c,d,e,f,g,h,i}   Vogelzang, Nicholas J ^{a,b,c,d,e,f,g,h,i}   Thompson, Ian M ^{a,b,c,d,e,f,g,h,i}   Glode, L Michael ^{a,b,c,d,e,f,g,h,i}  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Southwest Oncology Group   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ Comprehensive Cancer Centers of Nevada ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; GOSERELIN; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADULT; AGED; AMNESIA; ANDROGEN DEPRIVATION THERAPY; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FATALITY; FOLLOW UP; GLEASON SCORE; GYNECOMASTIA; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; OVERALL SURVIVAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RASH; URINE INCONTINENCE;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; GOSERELIN; HUMANS; MALE; MIDDLE AGED; MITOXANTRONE; NITRILES; PROSTATECTOMY; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 79956304214     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.2776     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Carver BS, Bianco FJ Jr, Scardino PT, et al: Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 176:564-568, 2006 (Pubitemid 43927886)
3. Petrovich Z, Lieskovsky G, Stein JP, et al: Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int 89:604-611, 2002 (Pubitemid 34948309)
4. Roehl KA, Han M, Ramos CG, et al: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 172:910-914, 2004 (Pubitemid 39096421)
5. Nguyen CT, Reuther AM, Stephenson AJ, et al: The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival. J Urol 181:75-80, 2009
6. Pilepich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997 (Pubitemid 27106285)
7. Roach M 3rd, Bae K, Speight J, et al: Shortterm neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 26:585-591, 2008 (Pubitemid 351264352)
8. Messing EM, Manola J, Yao J, et al: Immediate versus deferred androgren deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472-479, 2006 (Pubitemid 43779173)
9. Ravdin PM, Green S, Dorr TM, et al: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group Study. J Clin Oncol 10:1284-1291, 1992
10. Scher HI, Buchanan G, Gerald W, et al: Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11:459-476, 2004 (Pubitemid 39331277)
11. Magi-Galluzzi C, Zhou M, Reuther AM, et al: Neoadjuvant docetaxel treatment for locally advanced prostate cancer. Cancer 110:1248-1254, 2007 (Pubitemid 47435595)
12. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997 (Pubitemid 27318990)
13. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989 (Pubitemid 19211484)
14. Eisenberger MA, Blumenstein BA, Crawford ED, et al: Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 339:1036-1042, 1998 (Pubitemid 28457865)
15. Tannock IF, Osoba D, Stockler MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996 (Pubitemid 26185452)
16. Clarke M, Collins R, Darby S, et al: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
17. Wang J, Halford S, Rigg A, et al: Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. BJU Int 86:675-680, 2000
18. Flaig TW, Tangen CM, Hussain MH, et al: Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 26:1532-1536, 2008
19. Bolla M, van Poppel H, Collette L, et al: Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 366:572-578, 2005 (Pubitemid 41140332)
20. Thompson IM, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term followup of a randomized clinical trial. J Urol 181:956-962, 2009
21. Iversen P, Johansson JE, Lodding P, et al: Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol 172:1871-1876, 2004
22. Jhaveri FM, Klein EA, Kupelian PA, et al: Declining rates of extracapsular extension after radical prostatectomy: Evidence for continued stage migration. J Clin Oncol 17:3167-3172, 1999 (Pubitemid 29470647)
23. Stephenson RA, Stanford JL: Population-based prostate cancer trends in the United States: Patterns of change in the era of prostate-specific antigen. World J Urol 15:331-335, 1997 (Pubitemid 127764016)
24. Galper SL, Chen MH, Catalona WJ, et al: Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 175:907-912, 2006 (Pubitemid 43200015)
25. Smith EB, Frierson HF Jr, Mills SE, et al: Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: Is there evidence for systematic upgrading? Cancer 94:2282-2287, 2002
26. Tsivian M, Sun L, Mouraviev V, et al: Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. J Urol 74:1090-1093, 2009
27. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation for prostate cancer. J Clin Oncol 24:4448-4456, 2006 (Pubitemid 46630983)
28. D'Amico AV, Denham JW, Crook J, et al: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420-2425, 2007 (Pubitemid 46999213)
29. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005 (Pubitemid 41124175)
30. Hussain M, Tangen CM, Higano C, et al: Absolute prostate-specific antigen value after androgen deprivaiton is a strong independent predictor of survival in new metastatic prostate cancer: Data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24:3984-3990, 2006 (Pubitemid 46630748)
31. Hussain M, Goldman B, Tangen C, et al: Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 27:2450-2456, 2009